ArticleInternational journal of chronic obstructive pulmonary disease2025
Low-Density Lipoprotein Cholesterol as a Protective Factor in COPD and Implications for Statin Therapy: A Multi-Omics Genetic Epidemiology Study.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a complex lung condition primarily affecting the airways and alveoli, characterized by persistent progressive airflow limitation. COPD ranks as the third leading cause of death worldwide, with its incidence and mortality rates escalating annually due to an aging population. This study aimed to explore the association between low-density lipoprotein cholesterol (LDL-C) and COPD, as well as the impact of statin drugs on the progression of COPD. Methods: Employing an integrated approach that encompasses observational studies, genetic epidemiology, and molecular biology, this research investigated the link between LDL-C and COPD using clinical survey data, genome-wide association study (GWAS) data, and transcriptomic data. Additionally, it assessed the potential role of statin drugs in the treatment of COPD. Results: The study discovered that LDL-C serves as a protective factor for COPD, and statin drugs may promote the progression of COPD by reducing LDL-C levels. This finding provides a new perspective on the metabolic disruptions in COPD and offers significant guidance for future therapeutic strategies. Conclusion: This research confirms the inverse correlation between LDL-C and COPD and reveals that statin drugs might influence the progression of COPD by affecting LDL-C levels. These findings underscore the importance of considering metabolic factors in COPD management and suggest new directions for therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.